Medicine and Public Issues - Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments - Part 1: Ethical and Scientiﬁc Issues

Aug 23, 2026

Upload by Anda

The article evaluates ethical concerns about using placebo controls in clinical trials when effective therapy is already available, and explains why placebo use may still be acceptable depending on the harm caused by deferring treatment. It critiques a strict interpretation of the Declaration of Helsinki and argues that active-control (noninferiority) trials often cannot reliably establish efficacy across many medical contexts. Informed consent and patient impact are central to the proposed ethical framework.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

The Ethics of Placebo Controls

The Declaration of Helsinki

Informed Consent in Placebo-Controlled Trials

Medicine and Public Issues Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments Part 1: Ethical and Scientiﬁc Issues Robert Temple, MD, and Susan S. Ellenberg, PhD In recent years, several authors have argued that placebo-controlled trials are invariably unethical when known effective therapy is available for the condition being studied, regardless of the condition or the consequences of deferring treatment. Some have also disputed the value of placebo-controlled trials in such a setting, asserting that the comparison of new treatment with old treatment is sufficient to establish efficacy and is all that should be of interest. This article considers the ethical concerns about use of placebo controls and describes the limited ability of activecontrol equivalence (also known as noninferiority) trials to establish efficacy of new therapies in many medical contexts. The authors conclude that placebo-controlled trials are not uniformly unethical when known effective therapies are available; rather, their acceptability is determined by whether the patient will be harmed by deferral of therapy. If patients are not harmed, such trials can ethically be carried out. Furthermore, active-control trials, although valuable, informative, and appropriate in many circumstances, often cannot provide reliable evidence of the effectiveness of a new therapy. Ann Intern Med. 2000;133:455-463 . For author affiliations and current addresses, see end of text. See editorial comment on pp 474-475 . lacebo-controlled trials are used extensively Pvelopment of new pharmaceuticals. They in the deare some- times challenged as unethical in settings in which patients could be treated with an existing therapy (1–7) . The issues of when placebo controls are ethically acceptable and when they are scientiﬁcally necessary are important and worthy of discussion. The Ethics of Placebo Controls The Declaration of Helsinki The Declaration of Helsinki (8) is an international document that describes ethical principles for clinical investigation. Those who contend that placebo controls are unethical whenever known effective therapy exists for a condition usually cite the following sentence in the Declaration as support for that position: “In any medical study, every patient—including those of a control group, if any—should be assured of the best proven diagnostic and therapeutic method.” We believe that an interpretation of this sentence as barring placebo controls whenever an effective treatment exists is untenable. First, the requirement that all patients receive the “best proven diagnostic and therapeutic method” would bar not only placebo-controlled trials but also active-control and historically controlled trials. When effective treatment exists, the patient receiving the investi- gational treatment instead of the established therapy is clearly not getting the best proven treatment. Second, it does not seem reasonable to consider as equivalent all failures to use known effective therapy. Historically, concerns about placebo use have usually arisen in the context of serious illness. There is universal agreement that use of placebo or otherwise untreated controls is almost always unethical when therapy shown to improve survival or decrease serious morbidity is available. But in cases in which the treatment does not affect the patient’s long-term health, an ethical imperative to use existing therapy is not plausible. Can it be, for example, that because topical minoxidil or oral ﬁnasteride can grow hair, a placebo-controlled trial of a new remedy for baldness is unethical? Is it really unethical to use placebos in short-term studies of drugs for allergic rhinitis, insomnia, anxiety, dermatoses, heartburn, or headaches in fully informed patients? We do not believe that there is a reasonable basis for arguing that such studies and many other placebocontrolled studies of symptom relief are unethical and

FAQs

When are placebo-controlled trials considered ethically acceptable if effective therapy exists?

They can be ethically carried out when deferring known effective therapy does not harm the patient. Patient risk from delay is the deciding factor.

Why is a blanket ban on placebo controls based on the Declaration of Helsinki not supported?

A strict reading would bar not only placebo-controlled trials but also active-control and historically controlled designs. It also fails to treat all failures to use known effective therapy as equivalent.

What limitations do active-control (noninferiority) trials have in proving new treatment efficacy?

Although informative and appropriate in many settings, they often cannot provide reliable evidence of effectiveness of a new therapy across many medical contexts.

Aug 23, 2026

Upload by Anda